iCeutica develops improved branded medicines with pharmaceutical partners and from its own pipeline, using its proprietary SoluMatrix™ Fine Particle Technology to make drug particles 10 to 200 times smaller than conventional particles. The scalable process is designed to address bioavailability, dose consistency, side effects and drug delivery, and has supported three FDA-approved products launched in the United States. Based in Princeton with an Australian registered office, iCeutica has applied the technology across pain and inflammation, oncology and respiratory disease programs.